Pfizer launches large study of oral COVID-19 prevention drug – National

0

Pfizer Inc said on Monday it has started a large study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.

The drugmaker and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop an easy-to-administer antiviral pill for COVID-19.

The mid-to-late-stage study will test Pfizer’s drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed asymptomatic COVID-19 infection.

Read more:
U.S. FDA approves COVID-19 boosters for some high-risk people as CDC mulls guidance

In the trial, PF-07321332, designed to block the activity of a key enzyme needed for the coronavirus to multiply, will be administered along with a low dose of ritonavir, an older medication widely used in combination treatments for HIV infection.

Story continues below advertisement

To date, Gilead Sciences Inc’s intravenous drug remdesivir is the only approved antiviral treatment for COVID-19 in the United States.


Click to play video: 'U.S. to donate half a billion additional Pfizer COVID-19 vaccines'







U.S. to donate half a billion additional Pfizer COVID-19 vaccines


U.S. to donate half a billion additional Pfizer COVID-19 vaccines

Pfizer has also started another study of PF-07321332 in non-hospitalized, symptomatic adult patients.

Merck and partner Ridgeback Biotherapeutics recently launched a late-stage trial of their experimental drug molnupiravir for prevention of the COVID-19 infection.

Molnupiravir is also being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of
hospitalization or death.

(Reporting by Manojna Maddipatla and Amruta Khandekar in Bengaluru; Editing by Krishna Chandra Eluri)




Source link

Denial of responsibility! NewsConcerns is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment